HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients.

Authors: Jin Li, Ning Li, Mudan Yang, Yanqiao Zhang, Diansheng Zhong, Meng Qiu, Linzhi Lu, Xiaoming Hou, Yanru Qin, Guoping Sun, Jun Deng, Zimin Liu, Bo Liu, Yuntao Ma, Jingdong Zhang, Futang Yang, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu,

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.440

Source: Full article

---

Abstract

440